Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Flexibility: A Study to Assess the Impact of Once Per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects With Non-Myeloid Malignancies With Anemia Due to Chemotherapy

NCT00144131 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00144131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Flexibility: A Study to Assess the Impact of Once Per Cycle Correction and Maintenance Dosing of Darbepoetin Alfa in Subjects With Non-Myeloid Malignancies With Anemia Due to Chemotherapy
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2005
Completion date
Not reported
Enrollment
750
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, cancer